Tag: cause

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Pelican Acquisition II Corporation (NASDAQ: PLCIU) (the “Company”), a Cayman Islands exempted company, announced that it priced its initial public offering of 7,500,000 units at $10.00 per unit on July 23, 2026. The units will be listed on the Nasdaq Capital Market (“NASDAQ”) and are expected to trade under the ticker symbol “PLCIU” beginning on July 24, 2026. Each unit consists of one ordinary share of the Company and one right, with each right entitling the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.  

Cheyenne, Wyoming, July 23, 2026 (GLOBE NEWSWIRE) -- Core Axis, a health brand founded by MC Bio-Logic LLC, announces the upcoming launch of its daily supplement protocol developed with Hashimoto's thyroiditis in mind. Hashimoto's thyroiditis is the autoimmune condition that affects an estimated five million Americans and remains the leading cause of hypothyroidism in the United States. Designed using evidence-based ingredient selection and clinically relevant dosages, the new protocol addresses nutritional factors relevant to individuals with autoimmune thyroid conditions rather than providing general thyroid support. The company is now inviting individuals to join its early access waitlist ahead of the official product launch.

Bengaluru, India, July 23, 2026 (GLOBE NEWSWIRE) -- Zoomcar Holdings, Inc. (OTCQB: ZCAR) (the “Company”), the leading peer-to-peer self-drive car-sharing marketplace in India, today announced that it is extending the expiration date of its previously announced offer to exchange (the “Offer to Exchange”) certain outstanding warrants for shares of the Company’s common stock.

Second Quarter 2026

Ness Ziona, Israel, July 22, 2026 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH), a global leader in 3D-printing technology for production of whole cuts of plant-based meat, today announced its plan to adjust the ratio of the company's American Depositary Shares (ADSs) in relation to its ordinary shares. The adjustment will change the current ratio from one (1) ADS representing four thousand (4,000) ordinary shares to a new ratio of one (1) ADS representing twelve thousand (12,000) ordinary shares, effective on July 27, 2026. Steakholder Foods' ADSs will continue to be traded on the Nasdaq Capital Market under the ticker "STKH," with an updated CUSIP Number of 583435508.